ENDRA Life Sciences Inc. – Consensus Indicates Potential 628.2% Upside

Broker Ratings

ENDRA Life Sciences Inc. found using ticker (NDRA) now have 3 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 6 and 3.5 calculating the average target price we see 5.17. With the stocks previous close at 0.71 this would imply there is a potential upside of 628.2%. There is a 50 day moving average of 0.8 and the 200 day MA is 0.84. The market capitalisation for the company is $24m. Company Website: http://www.endrainc.com

ENDRA Life Sciences Inc. develops technology for clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood for the treatment of nonalcoholic fatty liver disease, as well as temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person’s body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp

AIM All Share Index